Gemcitabine–erlotinib versus gemcitabine–erlotinib–capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group

  1. Irigoyen, A.
  2. Gallego, J.
  3. Guillén Ponce, C.
  4. Vera, R.
  5. Iranzo, V.
  6. Ales, I.
  7. Arévalo, S.
  8. Pisa, A.
  9. Martín, M.
  10. Salud, A.
  11. Falcó, E.
  12. Sáenz, A.
  13. Manzano Mozo, J.L.
  14. Pulido, G.
  15. Martínez Galán, J.
  16. Pazo-Cid, R.
  17. Rivera, F.
  18. García García, T.
  19. Serra, O.
  20. Fernández Parra, E.M.
  21. Hurtado, A.
  22. Gómez Reina, M.J.
  23. López Gomez, L.J.
  24. Martínez Ortega, E.
  25. Benavides, M.
  26. Aranda, E.
  27. Erakutsi egile guztiak +
Aldizkaria:
European Journal of Cancer

ISSN: 1879-0852 0959-8049

Argitalpen urtea: 2017

Alea: 75

Orrialdeak: 73-82

Mota: Artikulua

DOI: 10.1016/J.EJCA.2016.12.032 GOOGLE SCHOLAR